Xcout Intel
Elicera Therapeutics
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Subscribe to see Elicera Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Elicera Therapeutics at a glance
Elicera Therapeutics is a biotech company headquartered in Sweden. Xcout tracks 10 named people at Elicera Therapeutics, including Ingvar Karlsson (Chief Financial Officer).
Elicera Therapeutics leadership
- Ingvar KarlssonChief Financial Officer
- Margareth JorvidChairman of the Board
- Jamal El-MoslehCEO and co-founder
- Di YuChief Development Officer and co-founder
- Magnus EssandChief Scientific Officer and co-founder
- Anna Koptina GültekinHead of Regulatory Affairs
4 more named people on record for Elicera Therapeutics, with roles, board committees and tenure — see the full roster →
Elicera Therapeutics competitors
A few of Elicera Therapeutics's closest competitors — see the full list of competitors and alternatives →
Tiankeya (also known as Beijing TCR Cure Biopharma Technology Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in China, with operations in China and the United States. The company focuses on the innovation, development, and clinical translation of engineered T cell and immune cell therapies to treat cancer and solid tumors.
Epicrispr Biotechnologies is a pioneering therapeutics company dedicated to developing advanced genetic medicines. The organization focuses on scientific research, platforms, and clinical pipelines to treat serious diseases.
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
KiraGen Bio is a Boston-based biotechnology company pioneering the development of AI-driven, multiplex gene-edited CAR-T cell therapies designed to target and block tumor suppression.
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.
Get Elicera Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Elicera Therapeutics in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access